Amanda Sheldon

What happens when you bring AI-powered clinical research into everyday patient care? Lu de Souza, MD FAMIA 🏳️‍🌈 tells us all the goodness happening now, and what's on the horizon. Excellent episode discussing the challenges and opportunities to accelerate and integrate clinical research findings with clinical care to make more informed decisions for better patient outcomes. 🎧 🎙 LISTEN: https://lnkd.in/evnj7z8d

14

Warning. Medical Affairs ‘purists’ will be triggered by this podcast. 🚨 Like it or not, there is a revolution at hand for medical affairs teams. There will be those who embrace the change and ride the wave to a meaningful, collaborative, cross-functional role in pharma, and those who get left behind in the weeds of vanity metrics and disjointed tactics. Whether you're a new or veteran listener to my BioPharma Revolution podcast then you know we’re traveling in the fast lane with the pirates over here, so buckle up because this episode is a treasure chest full of medical affairs plunder. Our special guest is Carlos Eid, Cardiovascular Executive Medical Director at Novartis, and a self-confessed pirate of pharma. I saw him speak at a conference and knew right away that I had to have him on the show… and I’m so happy he accepted. What to expect from Carlos: - Reflections on the past present and future of medical affairs - Challenging our perceptions of what makes a brilliant industry medic - Understanding how functions can work collaboratively around patient outcomes - Answers to questions over the future value of field medical - Lessons on measuring impact beyond vanity metrics and tactical success - Practical and valuable medical education journey planning tips You can enjoy the show on most of your favourite podcast platforms so follow the link to access... 👉 https://lnkd.in/eQCsWB5T Already listened to the show, how did it make you feel?

52

16 Comments

It's heartening to see there's an increased focus on developing more sustainable practices across healthcare as a whole, but sustainable procurement in clinical labs remains in its infancy. Vizient, Inc's Mellissa Nguyen and Yoav Einy argue that we can, and should, harness the potential of environmental stewardship to evolve current laboratory practices. Here's their advice on how to get started: https://lnkd.in/gDQCQ9RB

10

1 Comment

Another great episode! Tips to address challenges and reframe, acknowledge & influence skeptical audiences.

3

Many innovative ideas can become obscured when communicated, which was a significant challenge for Patient Blood Management #PBM as it was introduced to benefit those suffering from #anemia, in hopes of enabling surgery without the use of donated blood upon leaving the ER (Emergency Room). The PBM educational approach supports bloodless surgical procedures. To reduce this obscurity, we are simplifying the message and increasing awareness, benefiting #researchers, manufacturers, and healthcare practitioners. Most importantly, we are enhancing the patient experience and raising public awareness. We are confident that many global organizations, healthcare providers, and blood management surgical equipment manufacturers will support our efforts as we continue to be pioneers in building a bridge of engagement for public access, which will benefit this field of medicine. Remember our medical icons, just in case one day you need direction to the OR. #Bloodlines #BBTS #Blood #SABM

6

Getting ready for #ASCO24? So is Real Chemistry. Check out our latest report on how the #healthcare industry can more effectively use social media to promote early #cancer screenings in young adults.

7

Triple Negative Breast Cancer Clinical Trials, Treatment Drugs, Pipeline Insights, and Companies 2024: DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also … Continue reading → #PharmaceuticalsBiotech

3

Great wrap-up of Digital Pharma East in Fierce Pharma's "The Top Line" podcast with Andrea Park and Ben Adams. Lots of updates in an 8-minute podcast! Quick overview: 1) #ChatGPT banned internally by 20 Top #BioPharma firms. They are still working out how #AI can be helpful in marketing. Finding benefits particularly with #omnichannel approach and analyzing data, matching content and audiences. 2) #Omnichannel coming into its own. 3) Top #Pharma companies moving marketing services in house and away from agencies (Bayer brought media buying in-house 4 years ago, and they are seeing $$ benefits). 4) Digital Pharma East to become part of Fierce Pharma Week in 2025. https://lnkd.in/eMpVAr67 #biopharmamarketing #pharmasales

2

"When digital transformation is done right, it's like a caterpillar turning into a butterfly, but when it is done wrong, all you have is a really fast caterpillar," says author and MIT lecturer George Westerman. A great first step to "being the butterfly" are the insights that Megan Jones and Uttama Rath share below. ⬇

13

All three #GLP-1s — #semaglutide, #tirzepatide, and liraglutide — offer significant benefits in managing type 2 diabetes and #weightloss but differ in their administration schedules, efficacy, and additional benefits. We are breaking down how they differ in our latest insight article.

3